

**INDEPENDENT AUDITOR'S REPORT**

**To the Members of M/s Strides Pharma Services Private Limited**

**Report on the Ind AS financial statements**

**Opinion**

We have audited the accompanying Ind AS financial statements of M/s Strides Pharma Services Private Limited ("the Company"), which comprise the Balance Sheet as at 31<sup>st</sup> March, 2026, the Statement of Profit and Loss (including Other Comprehensive Income), Statement of Changes in Equity and the Statement of Cash Flows for the year then ended, and notes to the financial statements including material accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, the profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

**Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's *Code of Ethics*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

**Information other than the Financial Statements and Auditor's Report thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report, but does not include the financial statements and our auditor's report thereon.

The Board's Report is expected to be made available to us after the date of this Auditors' Report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

When we read Board's Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.



**Responsibility of the Management and those charged with governance for the financial statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, other comprehensive income, changes in equity and cash flows of the Company in accordance with Ind AS and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is included in "Annexure - A" of this auditor's report.

**Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2020 ("the order"), issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the **Annexure - B** a statement on the matters specified in paragraphs 3 and 4 of the order.
2. As required by Section 143(3) of the Act, we report that:
  - a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
  - b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
  - c. The Balance Sheet, the Statement of Profit & Loss including Other Comprehensive Income, Statement of Changes in Equity and the Statement of Cash Flows dealt with by this report are in agreement with the books of account;



- d. In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with the relevant rules issued there under;
- e. On the basis of the written representations received from the directors as on 31<sup>st</sup> March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31<sup>st</sup> March, 2026 from being appointed as a director in terms of Section 164(2) of the Act;
- f. With respect to the other matters to be included in the Auditors' Report in accordance with the requirements of Section 197(16) of the Act, as amended, the Company has not paid / provided any remuneration to its Directors during the year.
- g. With respect to the adequacy of internal financial controls over financial reporting of the company and the operating effectiveness of such controls, we give a separate report in the Annexure - C; and
- h. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position;
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv. The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that causes us to believe that the above representations given by the Management contain any material misstatement.
  - v. The Company has not declared or paid any dividend during the year and has not proposed final dividend for the year.



- vi. Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility that was enabled at the application level and the same has operated throughout the year for all relevant transactions recorded in the software system. Further, during the course of our audit, we did not come across any instance of audit trail feature being tampered with and the audit trail has been preserved by the Company as per the statutory requirements for record retention.

Place: Bengaluru  
Date: 8 May 2026



For GNANOBA & BHAT  
Chartered Accountants  
Firm Regn No. 000939S

R. UMESH  
Partner  
M. No. 027892  
UDIN: 26027892BUWRUC5637

ANNEXURE-A TO THE AUDITOR'S REPORT

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls systems in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable related safeguards.

Place: Bengaluru  
Date: 8 May 2026



For GNANOBA & BHAT  
Chartered Accountants  
Firm Regn No. 0009395

R. UMESH  
Partner  
M. No. 027892  
UDIN: 26027892BUWRUC5637

**ANNEXURE - B TO AUDITOR'S REPORT REFERRED TO IN PARAGRAPH 1 OF OUR REPORT OF  
EVEN DATE**

- (i) In respect of its Property, Plant and Equipment, since the Company did not carry any such assets in its books during the year under report, Clause (i) of Paragraph 4 of the said Order is not applicable.

According to the information and explanations given to us and based on our examination of the relevant records, no proceedings have been initiated or are pending against the company for holding any benami property under Benami Transactions (Prohibition) Act, 1988 and rules made thereunder, and hence clause (i)(e) of the order is not applicable.

- (ii) In respect of inventory, since the Company is engaged in the business of providing business support services and does not carry any inventory. Further, the Company has not availed of any working capital limits from a bank or a financial institution. Accordingly, clause (ii) of the order is not applicable.
- (iii) According to the information and explanations given to us and based on our examination of the relevant records, the Company has not made any investments, granted loans or advances in the nature of loans or provided any guarantee or security to any entity. Accordingly, reporting under this clause is not applicable.
- (iv) In our opinion and according to the information and explanations given to us and based on our examination of the relevant books and records as produced before us, the Company has not entered into any transactions which come under the purview of Section 185 and 186 of the Companies Act, 2013 and hence clause (iv) of the Order is not applicable.
- (v) In our opinion and according to the information and explanations given to us and based on our examination of the relevant books and records as produced before us, the Company has not accepted any deposits from the public in terms of Chapter-V the Companies Act, 2013 read with The Companies (Acceptance of Deposits) Rules, 2014 and no order has been passed by Company Law Board or National Company Law Tribunal or any other Tribunal. Hence reporting under this clause is not applicable.
- (vi) To the best of our knowledge and as explained to us, the Central Government has not specified the maintenance of cost records under sub-section 1 of section 148 of the Companies Act, 2013.
- (vii) According to the information and explanations given to us and on the basis of examination of the books and records as produced before us, in respect of statutory dues and other dues:
- a) The Company has been generally regular in depositing undisputed statutory dues, including Goods and Service Tax, Income Tax, Custom Duty, Cess and other statutory dues with the appropriate authorities during the period wherever applicable. There were no material undisputed amounts in respect of the above statutory dues, which were in arrears as at 31st March 2026, for a period more than six months from the date they became due.
- b) There were no statutory dues which were not deposited on account of any dispute.
- (viii) According to the information and explanation given to us and based on our verification of the records and relevant documents, the Company has not surrendered or disclosed additional income during the year in the tax assessments under Income Tax Act, 1961. Hence reporting under this clause is not applicable.



- (ix) In respect of its loans and borrowings:
- a. According to the information and explanation given to us and based on our verification of the records and relevant documents, the Company has not defaulted in repayment of loan or other borrowings or in the payment of interest thereon to any lender.
  - b. According to the information and explanations given to us and on the basis of our audit procedures, the company has not been declared wilful defaulter by any bank or financial institution or other lender.
  - c. According to the information and explanations given to us and based on our verification of the records and relevant documents, during the year, the company has not availed term loans.
  - d. According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the financial statements of the company, during the year no funds have been raised by the company.
  - e. According to the information and explanations given to us and the procedures performed by us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiary. The company does not have any associate and joint venture.
  - f. According to the information and explanations given to us and the procedures performed by us, the company has not raised any loans during the year on the pledge of securities held in its subsidiary. The company does not have any associate and joint venture.
- (x) In respect of moneys raised by way of initial public offer, further public offer, preferential allotment and private placement of shares / convertible debentures:
- a. The Company has not raised moneys by way of initial public offer or further public offer during the year.
  - b. The company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
- (xi) In respect of fraud:
- a. To the best of our knowledge and belief, according to the information and explanations given to us by the Management and the records produced before us, no frauds were noticed or reported during the year.
  - b. As reported above, no frauds were noticed or reported during the year and hence report under sub-section (12) of section 143 is not applicable.
  - c. As represented to us by the management, the Company is not required to implement a whistleblower policy under the provisions of sub-section 9 of section 177 of the Act read with Rule 7 of the Companies (Meetings of Board and its Powers) Rules, 2014.
- (xii) The Company is not a Nidhi Company and hence this clause is not applicable.
- (xiii) In our opinion and according to the information and explanation given to us and based on our verification of the records and relevant documents, all transactions with related parties entered into by the Company are in compliance with section 188 of the Companies Act where applicable and the details of the same have been disclosed in the financial statements etc. as required by the applicable accounting standards. The Provisions of Section 177 are not applicable to the Company.




- (xiv) In our opinion and based on our examination, the company does not have an internal audit system and is not required to have an internal audit system as per provisions of the Companies Act, 2013 and hence reporting under this clause is not applicable.
- (xv) According to the information and explanation given to us by the Management and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with directors or persons connected with him and hence this clause is not applicable.
- (xvi) In our opinion and according to the information and explanation given to us,
- a. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.
  - b. The Company has not conducted any Non-Banking Financial or Housing Finance activities.
  - c. The Company is not a Core Investment Company as defined in the regulations made by the Reserve Bank of India.
  - d. As represented by the Management, the Group does not have any Core Investment Companies.
- (xvii) The Company has not incurred any cash loss during the financial year under report. The Company had incurred cash losses of INR 0.17 Mn in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year and hence reporting under this clause is not applicable.
- (xix) According to the information and explanations given to us and on the basis of the financial ratios, aging and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.
- (xx) According to the information and explanations given to us and based on our examination of the records of the Company, there were no amounts required to be spent under sub section (5) of section 135 of the Companies Act, 2013.
- (xxi) Since the company is not required to present consolidated financial statements as the accounts of its wholly owned subsidiary is consolidated with the ultimate holding company, reporting under this clause is not applicable.

Place: Bengaluru  
Date: 8 May 2026



For GNANOBA & BHAT  
Chartered Accountants  
Firm Regn No. 000939S

  
R. UMESH  
Partner  
M. No. 027892  
UDIN: 26027892BUWRUC5637

**ANNEXURE - C TO AUDITOR'S REPORT REFERRED TO IN PARAGRAPH G OF OUR REPORT OF  
EVEN DATE**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the  
Companies Act, 2013 ("the Act")**

We have audited the internal financial controls over the financial reporting of M/s Strides Pharma Services Private Limited ("the Company") as on 31<sup>st</sup> March 2026 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended as on that date.

**Management's Responsibility for Internal Financial Controls**

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India (ICAI).

These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor's Responsibility**

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

**Meaning of Internal Financial Controls over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.



A company's internal financial control over financial reporting includes those policies and procedures that:

- (1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company.
- (2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipt and expenditures of the company are being made only in accordance with authorisations of management and directors of the company.
- (3) Provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

**Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

**Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India, more particularly in view of the negligible level of transactions and operations carried on by the company.

Place: Bengaluru  
Date: 8 May 2026



For GNANOBA & BHAT  
Chartered Accountants  
Firm Regn No. 000939S

A handwritten signature in black ink, appearing to read "R. Umesh".

R. UMESH  
Partner

M. No. 027892  
UDIN: 26027892BUWRUC5637

**STRIDES PHARMA SERVICES PRIVATE LIMITED**

**BALANCE SHEET AS AT MARCH 31, 2026**

*Rs. In Million, except per share data*

| Particulars                                                                              | Note No. | As at       |             |
|------------------------------------------------------------------------------------------|----------|-------------|-------------|
|                                                                                          |          | 31-Mar-26   | 31-Mar-25   |
| <b>A ASSETS</b>                                                                          |          |             |             |
| <b>I Non-current assets</b>                                                              |          |             |             |
| (a) Investments                                                                          | 4        | 0.01        | 0.01        |
| <b>Total non-current assets</b>                                                          |          | <b>0.01</b> | <b>0.01</b> |
| <b>II Current assets</b>                                                                 |          |             |             |
| (a) Financial assets                                                                     |          |             |             |
| (i) Cash and cash equivalents                                                            | 5        | 0.01        | 0.03        |
| (ii) Other financial assets                                                              | 6        | 0.60        | -           |
| (b) Other current assets                                                                 | 7        | 0.36        | 0.27        |
| <b>Total current assets</b>                                                              |          | <b>0.97</b> | <b>0.30</b> |
| <b>TOTAL ASSETS</b>                                                                      |          | <b>0.98</b> | <b>0.31</b> |
| <b>B EQUITY AND LIABILITIES</b>                                                          |          |             |             |
| <b>I Equity</b>                                                                          |          |             |             |
| (a) Equity share capital                                                                 | 8        | 1.85        | 1.85        |
| (b) Other equity                                                                         | 9        | (1.72)      | (1.77)      |
| <b>Total Equity</b>                                                                      |          | <b>0.13</b> | <b>0.08</b> |
| <b>II Current liabilities</b>                                                            |          |             |             |
| (a) Financial liabilities                                                                |          |             |             |
| (i) Trade payables                                                                       |          |             |             |
| - Total outstanding dues of micro enterprises and small enterprises                      | 10       | -           | 0.00        |
| - Total outstanding dues of creditors other than micro enterprises and small enterprises |          | 0.23        | 0.22        |
| (b) Other current liabilities                                                            | 11       | 0.61        | 0.01        |
| (c) Current tax liabilities (net)                                                        | 12       | 0.01        | -           |
| <b>Total current liabilities</b>                                                         |          | <b>0.85</b> | <b>0.23</b> |
| <b>TOTAL EQUITY AND LIABILITIES</b>                                                      |          | <b>0.98</b> | <b>0.31</b> |

The accompanying notes are an integral part of the financial statements

In terms of our report attached

For **Gnanoba & Bhat**

Chartered Accountants

Firm Registration No. 000939S

**R Umesh**

Partner

Membership No. 027892

Place: Bengaluru

Date : May 08, 2026

For and on behalf of Board of Directors of

**Strides Pharma Services Private Limited**

CIN: U74140MH2022PTC466009

**Anurag Bhagania**

Director

DIN: 02299791

Place: Bengaluru

Date : May 08, 2026

**Chirag Dalal**

Director

DIN: 01200653

Place: Bengaluru

Date : May 08, 2026



**STRIDES PHARMA SERVICES PRIVATE LIMITED**
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026**
*Rs. In Million, except per share data*

| Particulars                                                                       | Note | Year ended  |               |
|-----------------------------------------------------------------------------------|------|-------------|---------------|
|                                                                                   |      | 31-Mar-26   | 31-Mar-25     |
| 1 Revenue from operations                                                         | 13   | 0.60        | -             |
| 2 Other income                                                                    | 14   | -           | 0.03          |
| <b>3 Total Income</b>                                                             |      | <b>0.60</b> | <b>0.03</b>   |
| <b>4 Expenses</b>                                                                 |      |             |               |
| (a) Finance costs                                                                 | 15   | 0.00        | 0.01          |
| (b) Other expenses                                                                | 16   | 0.54        | 0.19          |
| <b>Total</b>                                                                      |      | <b>0.54</b> | <b>0.20</b>   |
| <b>5 Profit before exceptional items and tax (3-4)</b>                            |      | <b>0.06</b> | <b>(0.17)</b> |
| 6 Exceptional items gain / (loss) (net)                                           |      | -           | -             |
| <b>7 Profit before tax (5+6)</b>                                                  |      | <b>0.06</b> | <b>(0.17)</b> |
| <b>8 Tax expense</b>                                                              | 17   |             |               |
| (a) Current tax                                                                   |      | 0.01        | -             |
| (b) Deferred tax expense / (benefit)                                              |      | -           | -             |
| <b>Total tax expenses</b>                                                         |      | <b>0.01</b> | <b>-</b>      |
| <b>9 Profit / (Loss) for the year (7-8)</b>                                       |      | <b>0.05</b> | <b>(0.17)</b> |
| <b>10 Other Comprehensive Income</b>                                              |      |             |               |
| A) (i) Items that will not be reclassified to profit or loss                      |      | -           | -             |
| (ii) Income tax relating to items that will not be reclassified to profit or loss |      | -           | -             |
| B) (i) Items that may be reclassified to profit or loss                           |      | -           | -             |
| (ii) Income tax relating to items that may be reclassified to profit or loss      |      | -           | -             |
| <b>Total Other comprehensive Income</b>                                           |      | <b>-</b>    | <b>-</b>      |
| <b>10 Total comprehensive income for the period</b>                               |      | <b>0.05</b> | <b>(0.17)</b> |
| <b>11 Earnings per equity share (nominal value of Rs. 10/- each) in Rs.</b>       |      |             |               |
| - Basic                                                                           | 18   | 0.26        | (0.94)        |
| - Diluted                                                                         |      | 0.26        | (0.94)        |
| The accompanying notes are an integral part of the financial statements           |      |             |               |

In terms of our report attached  
For **Gnanoba & Bhat**  
Chartered Accountants  
Firm Registration No. 000939S



**R Umesh**  
Partner  
Membership No. 027892  
Place: Bengaluru  
Date : May 08, 2026



For and on behalf of Board of Directors of  
**Strides Pharma Services Private Limited**  
CIN: U74140MH2022PTC466009



**Anurag Bhagania**  
Director  
DIN: 02299791  
Place: Bengaluru  
Date : May 08, 2026



**Chirag Dalal**  
Director  
DIN: 01200653  
Place: Bengaluru  
Date : May 08, 2026



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

**STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026**

*Rs. In Million, except per share data*

| Particulars                                                                | 31-Mar-26     | 31-Mar-25     |
|----------------------------------------------------------------------------|---------------|---------------|
| <b>A. Cash flow from operating activities</b>                              |               |               |
| Net Profit / (Loss) before tax                                             | 0.06          | (0.17)        |
| <b>Operating profit / (loss) before working capital changes</b>            | <b>0.06</b>   | <b>(0.17)</b> |
| <b>Changes in working capital:</b>                                         |               |               |
| (Increase)/decrease in other current assets                                | (0.69)        | -             |
| Increase/(decrease) in trade and other payables                            | 0.61          | 0.08          |
| <b>Net Change in working capital</b>                                       | <b>(0.08)</b> | <b>0.08</b>   |
| <b>Cash generated from operations</b>                                      | <b>(0.02)</b> | <b>(0.09)</b> |
| Income taxes paid                                                          | -             | -             |
| <b>Net cash flow generated from / (used in) operating activities (A)</b>   | <b>(0.02)</b> | <b>(0.09)</b> |
| <b>B. Cash flow from investing activities</b>                              |               |               |
| Purchase of long-term investments                                          | -             | -             |
| <b>Net cash flow (used in) investing activities (B)</b>                    | <b>-</b>      | <b>-</b>      |
| <b>C. Cash flow from financing activities</b>                              |               |               |
| Borrowings/(Repayment) of loan (net)                                       | -             | -             |
| <b>Net cash flow generated from financing activities (C)</b>               | <b>-</b>      | <b>-</b>      |
| <b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b>      | <b>(0.02)</b> | <b>(0.09)</b> |
| Cash and cash equivalents at the beginning of the year                     | 0.03          | 0.12          |
| <b>Cash and cash equivalents at the end of the year</b>                    | <b>0.01</b>   | <b>0.03</b>   |
| <b>Reconciliation of cash and cash equivalents with the Balance Sheet:</b> |               |               |
| Cash and cash equivalents as per Balance Sheet                             | 0.01          | 0.03          |
| Cash and cash equivalents at the end of the year *                         | <b>0.01</b>   | <b>0.03</b>   |
| <b>* Comprises:</b>                                                        |               |               |
| (a) Cash on hand                                                           | -             | -             |
| (b) Balances with banks - in current accounts                              | 0.01          | 0.03          |
| <b>Total</b>                                                               | <b>0.01</b>   | <b>0.03</b>   |
| The accompanying notes are an integral part of the financial statements    |               |               |

In terms of our report attached

For **Gnanoba & Bhat**

Chartered Accountants

Firm Registration No. 000939S



**R Umesh**

Partner

Membership No. 027892

Place: Bengaluru

Date : May 08, 2026

For and on behalf of Board of Directors of

**Strides Pharma Services Private Limited**

CIN: U74140MH2022PTC466009



**Anurag Bhagania**

Director

DIN: 02299791

Place: Bengaluru

Date : May 08, 2026



**Chirag Dalal**

Director

DIN: 01200653

Place: Bengaluru

Date : May 08, 2026



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

**STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2026**

*Rs. In Million, except per share data*

| <b>A) Equity share capital</b>                    |                             |              |
|---------------------------------------------------|-----------------------------|--------------|
| <b>Particulars</b>                                | <b>Amount</b>               |              |
| <b>Balance as at April 01, 2024</b>               |                             | <b>1.85</b>  |
| Changes in equity share capital during the period |                             | -            |
| <b>Balance as at March 31, 2025</b>               |                             | <b>1.85</b>  |
| Changes in equity share capital during the period |                             | -            |
| <b>Balance as at March 31, 2026</b>               |                             | <b>1.85</b>  |
| <b>B) Other equity</b>                            |                             |              |
| <b>Particulars</b>                                | <b>Reserves and Surplus</b> | <b>Total</b> |
|                                                   | <b>Retained earnings</b>    |              |
| <b>Balance as at April 1, 2024</b>                | (1.60)                      | (1.60)       |
| Profit / (Loss) for the period                    | (0.17)                      | (0.17)       |
| Total comprehensive income                        | (0.17)                      | (0.17)       |
| <b>Balance as at March 31, 2025</b>               | (1.77)                      | (1.77)       |
| Profit / (Loss) for the period                    | 0.05                        | 0.05         |
| Total comprehensive income                        | 0.05                        | 0.05         |
| <b>Balance as at March 31, 2026</b>               | (1.72)                      | (1.72)       |


The accompanying notes are an integral part of the financial statements

In terms of our report attached

**For Gnanoba & Bhat**

*Chartered Accountants*

Firm Registration No. 000939S



**R Umesh**

*Partner*

Membership No. 027892

Place: Bengaluru

Date : May 08, 2026

For and on behalf of Board of Directors of

**Strides Pharma Services Private Limited**

CIN: U74140MH2022PTC466009



**Anurag Bhagania**

*Director*

DIN: 02299791

Place: Bengaluru

Date : May 08, 2026

**Chirag Dalal**

*Director*

DIN: 01200653

Place: Bengaluru

Date : May 08, 2026



## STRIDES PHARMA SERVICES PRIVATE LIMITED

Notes forming part of financial statements for the year ended March 31, 2026

### I General Information

Strides Pharma Services Private Limited ("the Company") having registered office at Office No. 1 And 2, 1<sup>st</sup> Floor, Fine Mansion, Dr.D.N.Road, Fort, Mumbai - 400001, was incorporated on 11th July 2022. The Company, a wholly owned subsidiary of OneSource Specialty Pharma Limited is primarily a service provider providing business support services for all processes, sub-processes and all other activities performed in pharmaceutical and biopharmaceutical sector across the world.

During the current year, the Company has entered into a Composite Scheme of Arrangement and Amalgamation (Merger by Absorption) amongst Steriscience Specialties Private Limited ("Transferor Company 1"), Brooks Steriscience Limited ("BSL" / "Transferee Company 1" / "Transferor Company 2"), Steriscience Pte Limited ("Steriscience SG" / "Transferor Company 3"), Strides Pharma Services Private Limited (the "Company" / "SPSPL" / "Transferor Company 4") and OneSource Specialty Pharma Limited ("OneSource" / "Transferee Company 2") (the "Composite Scheme"), wherein Brooks Steriscience Limited, Steriscience Pte Limited and Strides Pharma Services Private Limited will be amalgamated with OneSource Specialty Pharma Limited. The Composite Scheme also provides for financial restructuring to set off the negative balance in the retained earnings account against the balance lying in the securities premium account. The Composite Scheme was approved by the Board of Directors at its meeting held on September 26, 2025.

The Company notes that OneSource Specialty Pharma Limited has received in-principle approval for the proposed Scheme of Arrangement. Further, the Board of Directors of OneSource met on March 06, 2026 to review the next steps in the process and, after due deliberation, has decided to undertake a further review before proceeding with the filing of the scheme application with the National Company Law Tribunal (NCLT).

During the previous year, pursuant to the business restructuring action undertaken by the Holding Company (Strides Pharma Sciences Limited), the National Company Law Tribunal, Mumbai bench vide its order dated November 14, 2024 accorded its approval for the Scheme of Arrangement for De-merger involving Strides Pharma Science Limited ("Strides"), Steriscience Specialties Private Limited ("Steriscience") and OneSource Specialty Pharma Limited ("OneSource"). The effective date for the de-merger is November 27, 2024 and the appointed date for recording the demerger for the purpose of financial reporting is April 1, 2024. Consequent to the above, the entire shareholding of the Company has been transferred to OneSource Specialty Pharma Limited. Accordingly, the disclosures in respect of related party transactions mandated by the relevant accounting standard have been made in these accounts.

### 2 Material accounting policies

#### A Basis for Preparation of Financial statements

The Company is a wholly owned subsidiary of OneSource Specialty Pharma Limited, a listed company which is required to prepare its financial statements in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. Accordingly, these financial statements are prepared in accordance with Ind AS under the historical cost convention on accrual basis with revenues recognized and expenses accounted on their accrual, including provisions / adjustments for committed obligations and amounts determined as payable or receivable during the year. Costs and earnings in excess of billings for the year are recognized as Unbilled Revenue.

Accounting policies are consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

The Company does not prepare consolidated accounts as the accounts of the subsidiary company viz., OneSource Softgels Pte. Ltd. (formerly Strides Softgels Pte. Ltd.), Singapore, is consolidated with the Holding Company (OneSource Specialty Pharma Limited).

#### B Cash Flow Statements

Cash flows are reported using the indirect method, whereby the profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities are segregated based on the available information.

#### C Revenue Recognition

##### Revenue from contract with customers:

The Company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. A 5-step approach is used to recognize revenue as below:

Step 1: Identify the contract(s) with a customer

Step 2: Identify the performance obligation in contract

Step 3: Determine the transaction price

Step 4: Allocate the transaction price to the performance obligations in the contract

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation



**STRIDES PHARMA SERVICES PRIVATE LIMITED****Notes forming part of financial statements for the year ended March 31, 2026****Sale of Services**

Revenue from services rendered, is recognized in the statement of profit and loss as the underlying services are performed. Upfront payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed. Costs and earnings in excess of billings for the year are recognized as Unbilled Revenue.

**D Taxation**

The current charge for income tax (if any) is calculated in accordance with the relevant tax regulations applicable to the Company.

Deferred tax assets and liabilities (if any) are recognized for future tax consequences attributable to the timing differences that result between the profit offered for income tax and the profit as per financial statements. Deferred tax assets and liabilities are measured as per the tax rates / laws that have been enacted or substantively enacted by the Balance Sheet Date.

**E Provisions**

A provision is recognized when the enterprise has a present obligation as a result of past event(s) which may result in a probable outflow of resources to settle the obligation and in respect of which a reasonable estimate can be made. Provisions are not discounted to their present value and are determined on the basis of the best estimate of the resources required to settle the obligation at the balance sheet date. These are reviewed at each Balance Sheet date and adjusted to reflect the current best estimates.

**F Earnings Per Share**

Earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the profit / (loss) after tax (including the post-tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income relating to dilutive potential equity shares, by the weighted average number of equity shares considered for deriving the basic earnings per share and also the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares. Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease the net profit per share and are deemed to be converted at the beginning of the period, unless they have been issued at a later date.

**G Financial instruments****Investment in subsidiary**

The Company has accounted for its investment in subsidiary at cost less impairment.

**H Impairment of assets****Impairment of investment in subsidiary**

The Company reviews its carrying value of investment in subsidiary at cost, annually, or more frequently when there is an indication for impairment. If the recoverable amount is less than its carrying amount, the impairment loss is accounted for.

**I Functional Currency**

The Financial Statements are presented in Indian rupees, which is the functional currency of the Company. Functional currency of an entity is the currency of the primary economic environment in which the entity operates. All amounts have been rounded-off to two decimal places to the nearest million, unless otherwise indicated.

**J Operating Cycle**

As mentioned above under 'General information', the Company is incorporated with an objective of providing business support services for all processes, sub-processes and all other activities performed in pharmaceutical and biopharmaceutical sector. Based on the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months. The above basis is used for classifying the assets and liabilities into current and non-current as the case may be.

3 The previous year's figures have been re-grouped/reclassified, where necessary to conform to current year's classification.

For and on behalf of Board of Directors of  
**Strides Pharma Services Private Limited**  
CIN: U74140MH2022PTC466009



**Anurag Bhagania**  
Director  
DIN: 02299791  
Date : May 08, 2026



**Chirag Dalal**  
Director  
DIN: 01200653  
Date : May 08, 2026



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

Notes forming part of financial statements for the year ended March 31, 2026

Rs. In Million, except per share data

**4 Investments -Non-current**

| Particulars                                                                                                                                                            | 31-Mar-26   | 31-Mar-25   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|
| <b>Investments in subsidiaries: (Carried at cost)</b>                                                                                                                  |             |             |
| <b>Equity shares, unquoted</b>                                                                                                                                         |             |             |
| - 1 (As at March 31, 2025: 1) share of USD 100 fully paid up in OneSource Softgels Pte.Ltd. (Formerly Strides Softgels Pte.Limited (refer note (i) & (ii) given below) | 0.01        | 0.01        |
| <b>Total</b>                                                                                                                                                           | <b>0.01</b> | <b>0.01</b> |

(i)At the meeting of the Board of Directors of the Company held on 30th August 2023, an investment of USD 100 into Strides Softgels Pte.Limited was approved.

(ii)Accordingly, on 21st March 2024 the Company subscribed to 1 Equity Share of Strides Softgels Pte.Limited at USD 100 per share (with face value of USD 100 per share).

**5 Cash and cash equivalents**

| Particulars          | 31-Mar-26   | 31-Mar-25   |
|----------------------|-------------|-------------|
| Balance with banks:  |             |             |
| - In current account | 0.01        | 0.03        |
| <b>Total</b>         | <b>0.01</b> | <b>0.03</b> |

**6 Other financial assets**

| Particulars      | 31-Mar-26   | 31-Mar-25 |
|------------------|-------------|-----------|
| Unbilled revenue | 0.60        | -         |
| <b>Total</b>     | <b>0.60</b> | <b>-</b>  |

**7 Other current assets**

| Particulars                                | 31-Mar-26   | 31-Mar-25   |
|--------------------------------------------|-------------|-------------|
| <b>considered good:</b>                    |             |             |
| Balances with government authorities:      |             |             |
| - GST receivable                           | 0.36        | 0.27        |
| - Excess remittance of TDS (CY : Rs.1,738) | 0.00        | -           |
| <b>Total</b>                               | <b>0.36</b> | <b>0.27</b> |

**8 Equity share capital**

| Particulars                                                                                           | 31-Mar-26   | 31-Mar-25   |
|-------------------------------------------------------------------------------------------------------|-------------|-------------|
| <b>Authorised</b>                                                                                     |             |             |
| 500,000 Equity shares of Rs. 10/- each with voting rights (PY: 500,000 Equity shares of Rs.10/- each) | 5.00        | 5.00        |
| <b>Issued, subscribed and fully paid-up</b>                                                           |             |             |
| 185,000 Equity shares of Rs.10/- each with voting rights (PY:185,000 Equity shares of Rs.10/- each)   | 1.85        | 1.85        |
| <b>Total</b>                                                                                          | <b>1.85</b> | <b>1.85</b> |

**(a) Reconciliation of the number of shares**

| Particulars                  | 31-Mar-26       |                  | 31-Mar-25       |                  |
|------------------------------|-----------------|------------------|-----------------|------------------|
|                              | No. of Shares   | Amount in Rs.    | No. of Shares   | Amount in Rs.    |
| Equity share of Rs.10/- each |                 |                  |                 |                  |
| Opening balance              | 1,85,000        | 18,50,000        | 1,85,000        | 18,50,000        |
| Issued during the year       | -               | -                | -               | -                |
| <b>Closing balance</b>       | <b>1,85,000</b> | <b>18,50,000</b> | <b>1,85,000</b> | <b>18,50,000</b> |

**(b) Detail of the rights, preferences and restrictions attaching to each class of shares outstanding Equity shares of Rs. 10/- each:**

The Company has only one class of equity shares, having a par value of Rs.10/-. The holder of equity shares is entitled to one vote per share. In the event of liquidation of the Company, the holders of the equity shares will be entitled to receive any of the remaining assets of the Company, after distribution to all other parties concerned. The distribution will be in proportion to number of equity shares held by the shareholders.

**(c) Shares held by holding company:**

| Particulars                                                                            | 31-Mar-26   | 31-Mar-25   |
|----------------------------------------------------------------------------------------|-------------|-------------|
| <b>Equity shares of ₹10/- each fully paid held by</b>                                  |             |             |
| Onesource Specialty Pharma Limited (Holding Company from April 1, 2024) (refer note 1) | 1,85,000    | 1,85,000    |
| <b>% of holding</b>                                                                    | <b>100%</b> | <b>100%</b> |

**(d) Details of equity shares held by each shareholder holding more than 5% of equity shares:**

| Particulars                                   | 31-Mar-26   | 31-Mar-25   |
|-----------------------------------------------|-------------|-------------|
| <b>Equity shares of ₹10/- each fully paid</b> |             |             |
| Onesource Specialty Pharma Limited            |             |             |
| Number of shares held                         | 1,85,000    | 1,85,000    |
| <b>% of holding</b>                           | <b>100%</b> | <b>100%</b> |

**Note 1:** Of 185,000, 10 shares are held by Trisha A as nominee of Onesource Specialty Pharma Limited.



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

Notes forming part of financial statements for the year ended March 31, 2026

**9 Other equity**
*Rs. In Million, except per share data*

| Particulars                                    | 31-Mar-26     | 31-Mar-25     |
|------------------------------------------------|---------------|---------------|
| <b>Surplus in statement of profit and loss</b> |               |               |
| Opening balance                                | (1.77)        | (1.60)        |
| Add: Profit / (Loss) for the year              | 0.05          | (0.17)        |
| <b>Closing balance</b>                         | <b>(1.72)</b> | <b>(1.77)</b> |

**10 Trade payables:**

| Particulars                                                         | 31-Mar-26   | 31-Mar-25   |
|---------------------------------------------------------------------|-------------|-------------|
| Trade payables:                                                     |             |             |
| - Total outstanding dues of micro enterprises and small enterprises | -           | 0.00        |
| - Other than micro & small enterprises                              | 0.23        | 0.22        |
| <b>Total</b>                                                        | <b>0.23</b> | <b>0.22</b> |

Trade payables ageing schedule for the year ended March 31, 2026

| Particulars                          | Not due     | Outstanding for the following periods from the due date |             |             |                   | Total       |
|--------------------------------------|-------------|---------------------------------------------------------|-------------|-------------|-------------------|-------------|
|                                      |             | Less than 1 year                                        | 1-2 years   | 2-3 years   | More than 3 years |             |
| <b>Undisputed</b>                    |             |                                                         |             |             |                   |             |
| - MSME (micro and small enterprises) | -           | -                                                       | -           | -           | -                 | -           |
| - Others                             | 0.03        | 0.04                                                    | 0.11        | 0.05        | -                 | 0.23        |
| <b>Disputed</b>                      |             |                                                         |             |             |                   |             |
| - MSME (micro and small enterprises) | -           | -                                                       | -           | -           | -                 | -           |
| - Others                             | -           | -                                                       | -           | -           | -                 | -           |
| <b>Total</b>                         | <b>0.03</b> | <b>0.04</b>                                             | <b>0.11</b> | <b>0.05</b> | <b>-</b>          | <b>0.23</b> |

Trade payables ageing schedule for the year ended March 31, 2025

| Particulars                          | Not due     | Outstanding for the following periods from the due date |             |           |                   | Total       |
|--------------------------------------|-------------|---------------------------------------------------------|-------------|-----------|-------------------|-------------|
|                                      |             | Less than 1 year                                        | 1-2 years   | 2-3 years | More than 3 years |             |
| <b>Undisputed</b>                    |             |                                                         |             |           |                   |             |
| - MSME (micro and small enterprises) | -           | -                                                       | -           | -         | -                 | -           |
| - Others                             | 0.05        | 0.11                                                    | 0.05        | -         | -                 | 0.22        |
| <b>Disputed</b>                      |             |                                                         |             |           |                   |             |
| - MSME (micro and small enterprises) | -           | -                                                       | -           | -         | -                 | -           |
| - Others                             | -           | -                                                       | -           | -         | -                 | -           |
| <b>Total</b>                         | <b>0.05</b> | <b>0.11</b>                                             | <b>0.05</b> | <b>-</b>  | <b>-</b>          | <b>0.22</b> |

Note: (i) Disclosure required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

| Particulars                                                                                                                                                | 31-Mar-26 | 31-Mar-25 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------|
| (i) Principal amount remaining unpaid as at the end of the accounting year (CY: Nil & PY: INR 1,770)                                                       | -         | 0.00      |
| (ii) Interest due on the above remaining unpaid as at the end of the accounting year                                                                       | -         | -         |
| (iii) The amount of interest paid along with the amounts of the payment made beyond the appointed day                                                      | -         | -         |
| (iv) The amount of interest due and payable for the period of delay in making payment but without adding the interest specified under the MSMED Act, 2006; | -         | -         |
| (v) The amount of interest accrued and remaining unpaid at the end of the accounting year (CY: INR 122)                                                    | 0.00      | -         |
| (vi) The amount of further interest due and payable even in the succeeding year, until such date when the interest dues as above are actually paid         | -         | -         |

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management.

**11 Other Current liabilities**

| Particulars                             | 31-Mar-26   | 31-Mar-25   |
|-----------------------------------------|-------------|-------------|
| - Statutory liabilities                 | 0.01        | 0.01        |
| - Advance from customer (refer note 19) | 0.60        | -           |
| <b>Total</b>                            | <b>0.61</b> | <b>0.01</b> |

**12 Current tax liabilities**

| Particulars                                        | 31-Mar-26   | 31-Mar-25 |
|----------------------------------------------------|-------------|-----------|
| Provision for taxes (net of taxes paid in advance) | 0.01        | -         |
| <b>Total</b>                                       | <b>0.01</b> | <b>-</b>  |



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

Notes forming part of financial statements for the year ended March 31, 2026

*Rs. In Million, except per share data*
**13 Revenue from operations**

| Particulars            | 31-Mar-26   | 31-Mar-25 |
|------------------------|-------------|-----------|
| Support service income | 0.60        | -         |
| <b>Total</b>           | <b>0.60</b> | <b>-</b>  |

**14 Other income**

| Particulars          | 31-Mar-26 | 31-Mar-25   |
|----------------------|-----------|-------------|
| Miscellaneous income | -         | 0.03        |
| <b>Total</b>         | <b>-</b>  | <b>0.03</b> |

**15 Finance costs**

| Particulars                                              | 31-Mar-26   | 31-Mar-25   |
|----------------------------------------------------------|-------------|-------------|
| Bank charges and commission (CY:INR 2,825 PY:INR 13,380) | 0.00        | 0.01        |
| <b>Total</b>                                             | <b>0.00</b> | <b>0.01</b> |

**16 Other expenses**

| Particulars                       | 31-Mar-26   | 31-Mar-25   |
|-----------------------------------|-------------|-------------|
| Rent                              | 0.08        | 0.08        |
| Legal and professional fees       | 0.35        | 0.03        |
| Audit Fees (refer note (i) below) | 0.09        | 0.05        |
| Miscellaneous expenses            | 0.02        | 0.02        |
| <b>Total</b>                      | <b>0.54</b> | <b>0.19</b> |

**(i) Payments to auditors comprises (net of GST credit):**

| Particulars                     | 31-Mar-26   | 31-Mar-25   |
|---------------------------------|-------------|-------------|
| Statutory audit fee             | 0.04        | 0.04        |
| Special audit fee               | 0.02        | 0.01        |
| Other services ( Certification) | 0.03        | -           |
| <b>Total</b>                    | <b>0.09</b> | <b>0.05</b> |

**17 Tax expense / (credit)**

| Particulars          | 31-Mar-26   | 31-Mar-25 |
|----------------------|-------------|-----------|
| Current tax expenses | 0.01        | -         |
| Deferred tax         | -           | -         |
| <b>Total</b>         | <b>0.01</b> | <b>-</b>  |

Reconciliation between the income tax expense and amounts computed by applying the income tax rate to profit before taxes is as follows:

| Particulars                                 | 31-Mar-26   | 31-Mar-25     |
|---------------------------------------------|-------------|---------------|
| Profit/(loss) before tax                    | 0.06        | (0.17)        |
| Less: Expenditure u/s 35D                   | 0.01        | -             |
| <b>Taxable income as per Income tax act</b> | <b>0.05</b> | <b>(0.17)</b> |
| Tax rate                                    | 26%         | 26%           |
| <b>Current tax expenses</b>                 | <b>0.01</b> | <b>-</b>      |
| Deferred tax expenses                       | -           | -             |
| <b>Total tax expenses</b>                   | <b>0.01</b> | <b>-</b>      |

**18 Earnings per share**

Basic EPS amounts are calculated by dividing the profit for the year attributable to equity holders by the weighted average number of equity shares outstanding during the year.

Diluted EPS amounts are calculated by dividing the profit attributable to equity holders by the weighted average number of equity shares outstanding during the year plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

The following table sets out the computation of basic and diluted earnings per share:

| Particulars                                                                    | Amount   | Amount   |
|--------------------------------------------------------------------------------|----------|----------|
| Profit for the year attributable to equity share holders                       | 0.05     | (0.17)   |
| <b>Shares</b>                                                                  |          |          |
| Weighted average number of equity shares outstanding during the year – basic   | 1,85,000 | 1,85,000 |
| Weighted average number of equity shares outstanding during the year – diluted | 1,85,000 | 1,85,000 |
| <b>Earnings per share</b>                                                      |          |          |
| Earnings per share of par value ₹ 10 – basic (₹)                               | 0.26     | (0.94)   |
| Earnings per share of par value ₹ 10 – diluted (₹)                             | 0.26     | (0.94)   |



**STRIDES PHARMA SERVICES PRIVATE LIMITED**

Notes forming part of financial statements for the year ended March 31, 2026

**19 Related Party Transactions:**
**List of related parties**

| Party where the control exists     | Name of the Related party                                           |
|------------------------------------|---------------------------------------------------------------------|
| Holding Company from April 1, 2024 | OneSource Specialty Pharma Limited                                  |
| Subsidiary Company                 | OneSource Softgels Pte.Ltd.<br>(Formerly Strides Softgels Pte.Ltd.) |
| Promoter Group Company             | Strides Pharma Science Limited                                      |
| Promoter Group Company             | Arco Lab Private Limited                                            |
| Key Managerial Personnel           | Shashidhar K L (Up to January 27, 2025)                             |
| Key Managerial Personnel           | Vinod Kumar Bhaskaran (Up to January 27, 2025)                      |
| Key Managerial Personnel           | Anurag Bhagania ( From January 24, 2025)                            |
| Key Managerial Personnel           | Naveen Madan ( From January 24, 2025 to November 03, 2025)          |
| Key Managerial Personnel           | Chirag Dalal ( From October 31, 2025)                               |

| Rs. In Million                                        |           |           |
|-------------------------------------------------------|-----------|-----------|
| Particulars                                           | 31-Mar-26 | 31-Mar-25 |
| <b>Rental expenses</b>                                |           |           |
| 1  Arco Lab Private Limited                           | 0.05      | 0.08      |
| <b>Reimbursement of expenses</b>                      |           |           |
| 1  OneSource Specialty Pharma Limited (PY: INR 1,885) | -         | 0.00      |

| Rs. In Million                        |           |           |
|---------------------------------------|-----------|-----------|
| Particulars                           | 31-Mar-26 | 31-Mar-25 |
| <b>Balance of payable</b>             |           |           |
| 1  Arco Lab Private Limited           | 0.20      | 0.14      |
| <b>Balance of trade advance</b>       |           |           |
| 2  Onesource Specialty Pharma Limited | 0.60      | -         |

**20 Operating Ratios**

| Ratio                                    | Numerator                                             | Denominator                                                                           | 31-Mar-26 |
|------------------------------------------|-------------------------------------------------------|---------------------------------------------------------------------------------------|-----------|
| Current ratio (in times)                 | Total current assets                                  | Total current liabilities                                                             | 1.14      |
| Return on equity ratio (in %)            | Profit for the year less preference dividend (if any) | Average total equity                                                                  | 44.93%    |
| Trade payables turnover ratio (in times) | Purchases + Other expenses                            | Average trade payable                                                                 | 2.35      |
| Net capital turnover ratio (in times)    | Revenue from operations                               | Average working capital<br>(i.e. Total current assets less Total current liabilities) | 10.34     |
| Net profit ratio (in %)                  | Profit for the year                                   | Total Income                                                                          | 7.81%     |
| Return on capital employed (in %)        | Profit before tax and finance costs                   | Capital employed = Net worth + Total debt - Deferred tax assets                       | 43.98%    |

Note: The Company commenced its commercial operations during the current financial year. Consequently, the relevant operating and profitability ratios have been computed and presented for the year under reporting only. Comparative ratios for the previous financial year are not applicable as there were no commercial operations.

